About: Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States
Creator	Gao, Xin Staginnus, Ulf Triulzi, Darrell Postma, Maarten Bell, Christopher Botteman, Marc Maryland, Pashos, Chris Weissfeld, Joel
Source	Elsevier; Medline; PMC
abstract	Abstract Background: The Intercept Blood System (IBS) for platelets has been developed to reduce pathogen transmission risks during transfusions. Objective: This study was a comprehensive economic analysis of the cost-effectiveness of using the IBS for single-donor apheresis platelets (AP) and random-donor pooled platelet concentrates (PC) versus AP and PC without the IBS in the United States in patient populations in which platelets are commonly transfused. Methods: All data used in this analysis were summarized from existing published sources (primarily indexed in MEDLINE) and data on file at Baxter Healthcare Corporation (Chicago, Illinois) and Cerus Corporation (Concord, California). A literature-based decision-analytic model was developed to assess the economic costs and clinical outcomes associated with the use of AP and PC treated with the IBS for several conditions and procedures that account for a considerable proportion of the platelet usage in the United States: acute lymphocytic leukemia, non-Hodgkin's lymphoma, coronary artery bypass graft, and hip arthroplasty Risks of infection with HIV, hepatitis C virus (HCV), hepatitis B virus, human T-cell lymphotropic virus type 1, or bacterial agents were incorporated into the model. Possible benefits of reduction of the risk of emerging HCV like pathogens and elimination of the need for gamma irradiation were explored in sensitivity analyses. Results: The incremental cost per quality-adjusted life-year gained by using AP + IBS versus untreated AP ranged from $1,308,833 to $4,451,650 (without bacterial testing) and $4,759,401 to $22,968,066 (with bacterial testing). Corresponding figures for PC + IBS versus untreated PC ranged from $457,586 to $1,816,060. Inclusion of emerging HCV like virus and the elimination of the need for gamma irradiation improved the cost-effectiveness to a range of $177,695 to $1,058,127 for AP without bacterial testing, $176,572 to $1,330,703 for AP with bacterial testing, and $22,888 to $153,564 for PC. The model was most likely to be affected by mortality from bacterial contamination, IBS effect on platelet utilization, and the inclusion of potential benefits (ie, gamma irradiation and/or emergent HCVlike virus). The model was relatively insensitive to changes in the IBS price and viral transmission risks. Conclusions: The cost-effectiveness of pathogen inactivation via the IBS for platelets is comparable to that of other accepted blood safety interventions (eg, nucleic acid amplification technology). The IBS for platelets may be considered a desirable strategy to increase the safety of platelet transfusions and a potential insurance against the threat of emerging pathogens.
has issue date	2003-09-30(xsd:dateTime)
bibo:doi	10.1016/s0149-2918(03)80288-6
bibo:pmid	14604745
has license	els-covid
sha1sum (hex)	b757b63173908e7dcd256e72ede22d6db7ea780a
schema:url	https://doi.org/10.1016/s0149-2918%2803%2980288-6
resource representing a document's title	Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States
has PubMed Central identifier	PMC7133650
has PubMed identifier	14604745
schema:publication	Clinical Therapeutics
resource representing a document's body	covid:b757b63173908e7dcd256e72ede22d6db7ea780a#body_text
is schema:about of	named entity 'The Intercept' named entity 'platelets' named entity 'TRANSFUSIONS' named entity 'INTERCEPT' named entity 'TO REDUCE' named entity 'TREATMENT' named entity 'PATHOGEN TRANSMISSION' named entity 'COST-EFFECTIVENESS' named entity 'PREPARED' named entity 'PATHOGEN' named entity 'COMPONENTS' named entity 'INACTIVATION' named entity 'PLATELET' named entity 'UNITED STATES' named entity 'TRANSFUSION' named entity 'RISKS' named entity 'BLOOD SYSTEM' named entity 'PLATELETS' covid:arg/b757b63173908e7dcd256e72ede22d6db7ea780a named entity 'risks' named entity 'Cost-Effectiveness' named entity 'Transfusion' named entity 'NHL' named entity 'Blood banks' named entity 'blood products' named entity '2.2' named entity 'orthopedic' named entity 'quality-of-life' named entity 'CABG' named entity 'blood components' named entity 'laboratory test' named entity 'HIV' named entity 'platelets' named entity 'mortality rate' named entity 'ICER' named entity 'cost-effectiveness' named entity 'Univariate analysis' named entity 'pathogen' named entity 'symptom' named entity 'QALY' named entity 'risk of transmission' named entity 'pathogen' named entity 'Probabilities' named entity 'risk of transmission' named entity 'platelet' named entity 'HTLV' named entity 'pathogen' named entity 'NHL' named entity 'NHL' named entity 'HIV/AIDS' named entity 'pediatric' named entity 'bloodborne' named entity 'platelets' named entity 'HTLV-1' named entity 'death rates' named entity 'HCV' named entity 'pediatric' named entity 'gamma irradiation' named entity 'GVHD' named entity 'platelet' named entity 'Monte Carlo simulations' named entity 'morbidity' named entity 'platelet' named entity 'sensitivity analysis' named entity 'cirrhosis' named entity 'sample size' named entity 'HBV' named entity 'HIV' named entity 'platelets' named entity 'weighted average' named entity 'HIV' named entity 'cost-effectiveness' named entity 'shelf-life'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software